RECENT ADVANCES IN ISATIN DERIVATIVES AS POTENTIAL ANTICANCER AGENTS: A MINI REVIEW

Ms. Neha D. Mahurkar
Assistant professor, Department of Chemistry, Mungasaji Maharaj Mahavidyalaya, Darwha. Dist. Yavatmal (MH)
nehad7mahurkar@gmail.com

Abstract:
A flexible heterocyclic scaffold, isatin (indole-2,3-dione) has garnered a lot of interest in medicinal chemistry because of its wide range of biological activities, especially its anticancer capabilities. Significant structural changes to isatin over the last ten years have produced new derivatives with improved efficacy, selectivity, and decreased toxicity. Promising candidates that can target several chemical pathways have been produced by substitutions at the N-1, C-3, and C-5 locations as well as hybridization with other pharmacophores such benzimidazole, quinoline, chalcone, and thiosemicarbazone. Through a variety of methods, such as kinase inhibition, apoptosis induction, cell cycle arrest, and disruption of DNA–topoisomerase interactions, these compounds produce their anticancer effects. The potential of chiral and hybrid isatin-based compounds as lead structures for next-generation chemotherapeutics has been highlighted in recent papers. In addition to discussing the mechanisms of action of isatin derivatives and outlining future prospects for their clinical translation, this short review reviews current developments (2015–2025) in their design and biological evaluation.
Keywords: *Isatin, Anticancer agents, Heterocycles, Drug design, Hybrid molecules*

1. Introduction:

According to recent WHO estimates, cancer causes around 10 million deaths a year, making it one of the leading causes of morbidity and mortality globally. Population growth, aging, lifestyle factors, and genetic predispositions all contribute to the rising worldwide cancer burden, despite impressive advancements in diagnostic and treatment approaches. Despite their occasional effectiveness, conventional chemotherapeutics are frequently linked to serious side effects, multidrug resistance, and poor selectivity for cancer cells. This emphasizes how urgently new anticancer drugs that are safer, more effective, and able to overcome drug resistance must be developed. Because of their structural diversity and capacity to interact with a variety of biological targets, heterocyclic scaffolds hold a pivotal role in medicinal chemistry. A favored pharmacophore with a broad variety of biological activities, such as antibacterial, antiviral, anti-inflammatory, and particularly anticancer properties, isatin (indole-2,3-dione) has emerged among them. Both naturally occurring and artificially engineered isatin derivatives have shown strong cytotoxic potential against a range of human cancer cell lines. Modifications at the N-1, C-3, C-5, and C-7 locations are possible due to the structural flexibility of the isatin nucleus, producing derivatives with increased potency, improved selectivity, and unique modes of action. By mixing the isatin nucleus with different pharmacophores such benzimidazole, quinoline, chalcone, and thiosemicarbazone, medicinal chemists have recently investigated isatin-based hybrids. These hybrid compounds have demonstrated enhanced anticancer profiles, superior pharmacokinetic characteristics, and synergistic actions. Additionally, mechanistic research indicates that isatin derivatives have a variety of therapeutic potentials, including the ability to produce cell cycle arrest, inhibit kinases, induce apoptosis, and disrupt DNA-topoisomerase interactions. This brief study aims to provide an overview of recent developments (2015–2025) in the synthesis, design, and biological assessment of isatin derivatives as anticancer medicines. Structural changes, hybridization tactics, mechanisms of action, and prospects for clinical development in the future are given special attention.

2. Structural Features of Isatin:



Indole-2,3-dione
(Isatin)

Figure 1: Structure and atomic numbering in Isatin nucleus

Early in the 19th century, it was discovered that isatin (1H-indole-2,3-dione) is a bicyclic heteroaromatic molecule that naturally results from the oxidation of indigo. Its extensive pharmacological profile and chemical adaptability have drawn constant attention to its basic indole-

based structure. Isatin is a special indole derivative with high reactivity because its core is made up of a fused benzene and pyrrole ring structure with two neighboring carbonyl groups at positions C-2 and C-3.Isatin's structural makeup provides a variety of chemical modification sites, which significantly influences its biological activity. In general, substitution at the N-1 position increases membrane permeability and lipophilicity, which affects bioavailability. Since the C-3 position has a reactive carbonyl group, it is very easy for Schiff bases, thiosemicarbazones, hydrazones, and oximes to form. Many of these compounds have strong cytotoxic and apoptosis-inducing properties. Similar to this, changes involving electron-donating or electron-withdrawing groups at positions C-5 and C-7 are crucial for adjusting electronic characteristics and enhancing target selectivity. The development of hybrid compounds, in which the isatin nucleus is covalently bonded to another pharmacophore, is one of the most crucial approaches in isatin-based medication design. This method combines two active scaffolds onto a single molecule, increasing structural diversity while simultaneously producing synergistic effects. In comparison to their parent compounds, isatin-benzimidazole, isatin-quinoline, isatin-chalcone, and isatin-thiosemicarbazone hybrids have demonstrated increased anticancer efficacy.

The ability of the isatin nucleus to interact with biological targets in a variety of ways accounts for its adaptability. The aromatic indole framework promotes π–π stacking and hydrophobic interactions with proteins and DNA, whereas the presence of two nearby carbonyl groups permits hydrogen bonding, metal coordination, and nucleophilic assault. Isatin derivatives' broad-spectrum pharmacological activity can be explained by these structural characteristics, which also make them a desirable model for creating new anticancer drugs.

3. Recent Advances in Isatin Derivatives as Anticancer Agents:



Figure 2:Versatile Nature of Isatin ***(Image reproduced with permission)***

In the study of anticancer drugs, isatin derivatives remain a significant class of heterocyclic chemicals. Their wide range of chemical properties enables structural alterations at several locations, resulting in derivatives with enhanced pharmacological profiles, potency, and selectivity. Both straightforward substitutions and hybrid approaches have been investigated recently, and preclinical research has shown encouraging results. Key structural alterations and their function in anticancer activity are highlighted in the ensuing subsections.

3.1. N-Substituted Isatin Derivatives: Many studies have looked into isatin's N-1 position as a site for substitution, especially with aryl and alkyl groups. Generally speaking, these changes increase lipophilicity, which raises membrane permeability and bioavailability. It has been shown that N-substituted derivatives exhibit strong action against colon, lung, and breast cancer cell lines. Because they can inhibit protein kinases involved in cell cycle regulation, N-benzyl isatin analogs, for instance, showed strong cytotoxicity with IC_{50} values in the low micromolar range. Additionally,

adding halogenated aryl groups at this location has been linked to enhanced apoptosis-inducing capabilities. According to these results, N-substituted isatins offer a straightforward but efficient approach to the development of novel anticancer drugs.

3.2. C-3 Substituted Derivatives: A flexible location for structural elaboration is the carbonyl group at the C-3 position. Many derivatives, including hydrazones, thiosemicarbazones, and Schiff bases, have been created and their anticancer potential evaluated. For example, via inducing mitochondrial apoptosis pathways, schiff base derivatives of isatin have demonstrated excellent growth inhibition against breast and cervical cancer cells. The ability of thiosemicarbazones to chelate metals makes them particularly intriguing since it can disrupt vital enzyme functions in tumor cells. It has also been shown that a number of hydrazone derivatives can cause apoptosis and stop the cell cycle at the G2/M phase, which increases cytotoxicity. All things considered, C-3 substitution has become a strong method for producing strong anticancer candidates with a variety of modes of action.



Figure 3: Isatin moiety containing active and potential drugs ***(Image reproduced with permission)***

3.3. Hybrid Molecules: The creation of hybrid molecules based on isatin has been one of the most fascinating avenues in recent years. Researchers have successfully integrated several modes of action into a single molecule by combining isatin with another pharmacophore. Isatin-benzimidazole, isatin-quinoline, and isatin-chalcone hybrids have demonstrated encouraging outcomes, frequently outperforming the activity of separate scaffolds. The growth of non-small cell lung carcinoma was strongly inhibited by isatin–quinoline conjugates, whereas hybrids of isatin and benzimidazole showed IC_{50} values as low as 2–5 µM against breast cancer cells. Likewise, isatin–chalcone hybrids have been shown to inhibit the invasion and migration of tumor cells, indicating their possible use in the fight against metastasis. These promising findings demonstrate the benefits of molecular hybridization in the development of next-generation anticancer medications.

3.4. Mechanistic Insights: Isatin derivatives' capacity to interact with a variety of molecular targets is what gives them their anticancer properties. Several derivatives impede unchecked cell proliferation by acting as strong kinase

inhibitors, especially against cyclin-dependent kinases (CDKs) and the epidermal growth factor receptor (EGFR). Others cause replication stress and death by binding to DNA either by intercalation or by blocking topoisomerase enzymes. Certain derivatives cause programmed cell death pathways, activate caspase cascades, and disrupt mitochondrial function. Crucially, isatin derivatives are less prone to resistance development, which is a significant disadvantage of contemporary chemotherapeutics, because to their complex mode of action. These substances have the potential to develop more potent and long-lasting cancer treatment methods by concurrently focusing on several routes.

4. Future Perspectives:

Even though research into isatin derivatives as anticancer medicines has advanced significantly, a number of obstacles must be overcome before these substances may be developed into medications that are effective in clinical settings. Only a small number of the reported compounds have been tested in vivo, and even fewer have advanced to preclinical or clinical trials, despite the fact that the majority have demonstrated excellent efficacy in vitro. In order to evaluate the true therapeutic potential of intriguing candidates, future research should concentrate on closing this gap by conducting comprehensive pharmacokinetic, pharmacodynamic, and toxicological studies. The design of chiral isatin derivatives is a crucial topic of study. Chirality frequently has a significant impact on both potency and safety profiles in drug–receptor interactions. Compounds with greater selectivity and fewer off-target effects could be produced by investigating enantiomerically pure isatin derivatives, which would lower toxicity. The creation of such chiral compounds is now more possible than ever because to developments in catalytic processes and asymmetric synthesis. Isatin hybridization with other bioactive scaffolds is another interesting tactic that has already shown notable gains in potency and selectivity. Future research might examine hybrid compounds that are specialized to angiogenesis, immunological regulation, or PI3K/Akt signaling, among other cancer pathways. By combining isatin with multitarget-directed ligands (MTDLs), it is also possible to target several cancer hallmarks at once and maybe overcome multidrug resistance. It is anticipated that advancements in drug creation will be accelerated by the incorporation of artificial intelligence (AI) and computational methods. It is possible to estimate binding affinities, optimize structural alterations, and precisely discover novel isatin-based chemotypes using molecular docking, virtual screening, and machine learning algorithms. In addition to cutting down on the time and expense needed for discovery, these methods will raise the likelihood of finding lead candidates with advantageous pharmacological characteristics. Additionally, the therapeutic applicability of isatin derivatives may be improved by the creation of targeted drug delivery systems through the use of nanotechnology. In order to minimize systemic toxicity and maximize therapeutic efficacy, prodrug methods and nanoformulations may enhance solubility, stability, and tumor-specific delivery. In summary, even if the anticancer potential of isatin derivatives is well supported by current research, in vivo validation, chiral drug design, hybridization techniques, AI-driven discovery, and sophisticated delivery systems should be given top priority in future investigations. Combining these strategies could soon enable the conversion of the encouraging lab results into anticancer treatments that are clinically feasible.

Conclusion:

As useful scaffolds in the creation of new anticancer drugs, isatin and its derivatives continue to draw interest. Derivatives with a wide range of modes of action and considerable cytotoxic potential have been created via structural alterations at the N-1, C-3, and other locations as well as hybridization with pharmacophores including benzimidazole, quinoline, and chalcone. These substances have a variety of therapeutic applications, including the inhibition of protein kinases, DNA interaction, and apoptosis induction. Even with these encouraging developments, most research is still restricted to in vitro tests. To verify safety and effectiveness in physiological conditions, thorough in vivo studies and clinical translation are urgently needed. Furthermore, there are intriguing prospects for improving selectivity and lowering toxicity through the investigation of chiral isatin derivatives. In the future, the combination of computer modeling and AI-driven drug design may speed up the discovery process and make it possible to find powerful lead compounds with ideal pharmacological characteristics.In conclusion, if future studies tackle translational issues and make use of cutting-edge technologies to realize their full therapeutic potential, isatin derivatives have a great chance of becoming next-generation anticancer drugs

References:

1. Awolade, P., Cele, N., Ebenezer, O., Kerru, N., Gummidi, L., Gu, L., Palma, G., Kaur, M., & Singh, P. (2021). Synthesis of 1H-1,2,3-triazole-linked quinoline–isatin molecular hybrids as anti-breast cancer and anti-MRSA

agents. *Anticancer Agents in Medicinal Chemistry, 21*(10), 1228–1239. doi:10.2174/1871520620666200929153138. Invalid URL

2. Busto, N., Cavaliere, A., de la Fuente, Á., Ibarrola, B., Martin-Encinas, E., & Moreno, D. (2022). N-1,2,3-triazole-isatin derivatives: Anti-proliferation effects and identification of protein targets. *RSC Medicinal Chemistry, 13*(8), 970–977. doi:10.1039/D2MD00044J. PubMed
3. Chowdhary, S., Shalini, Arora, A., & Kumar, V. (2022). A mini review on isatin, an anticancer scaffold with potential activities against neglected tropical diseases. *Pharmaceuticals, 15*(5), 536. doi:10.3390/ph15050536. MDPI
4. Eldehna, W. M., Fares, M., El-Deeb, N. M., Al-Rashood, S. T., Alharbi, A., & Abdel-Aziz, H. A. (2021). Development of novel benzofuran–isatin conjugates with dual tubulin polymerization inhibition and apoptosis induction as potential anticancer agents. *Journal of Enzyme Inhibition and Medicinal Chemistry, 36*(1), 1423–1434. doi:10.1080/14756366.2021.1944127. PubMed
5. Hou, Y., Shang, C., Wang, H., & Yun, J. (2020). Isatin–azole hybrids and their anticancer activities. *Archiv der Pharmazie, 353*, e1900272. doi:10.1002/ardp.201900272. PMC
6. Khedr, A. I., El-Sayed, A. M., Zaki, R. M., & Abdelwahab, S. F. (2024). An insight into isatin and its hybrid scaffolds as anti-cancer agents. *Discover Oncology, 15*, 1–27 (Article 75). doi:10.1007/s12672-024-00959-5. SpringerLink
7. Oubella, A., Laamarti, R., Essassi, E. M., et al. (2021). Synthesis and biological evaluation of isatin-thiazolo[3,2-a]benzimidazole hybrids as potential anticancer agents. *Bioorganic Chemistry, 115*, 105219. doi:10.1016/j.bioorg.2021.105219. ScienceDirect
8. Puthiaraj, P., Mohamed, M. G., Ramesh, S., et al. (2024). Synthesis of triazole-linked isatin–chalcone hybrids: Anticancer potency, bioavailability, and bioactivity assessment. *ChemMedChem, 19*(9), e202300808. doi:10.1002/cmdc.202300808. PubMed
9. Rasras, A. J., Abulaban, O. A., & Abu-Jarour, R. J. (2021). Anticancer compounds based on isatin derivatives: Strategies to improve selectivity and efficacy. *Frontiers in Molecular Biosciences, 8*, 627272. doi:10.3389/fmolb.2021.627272. PMC
10. Shaldam, M. A., Abu-Ali, O. A., El-Sayed, A. A., et al. (2023). Design of sulfonamide-tethered isatin derivatives as VEGFR-2 inhibitors with anticancer potential. *Journal of Enzyme Inhibition and Medicinal Chemistry, 38*(1), 2203389. doi:10.1080/14756366.2023.2203389. PMC
11. Singh, S., Awasthi, S. K., & Tripathi, R. P. (2022). Design, synthesis, and biological evaluation of morpholinated isatin–quinoline hybrids as anticancer agents. *Archiv der Pharmazie, 355*(2), e2100368. doi:10.1002/ardp.202100368. PubMed
12. Vilar, S., Mosquera, M. E. G., & Ruso, J. M. (2020). Therapeutic potential of aromatic hydrazones: Focus on anticancer activity. *Molecules, 25*(19), 4400. doi:10.3390/molecules25194400. (Includes isatin-based hydrazones.) PubMed
13. Wang, R., Huang, R., Yuan, Y., Wang, Z., & Shen, K. (2023). The anti-breast cancer potential of indole/isatin hybrids. *Archiv der Pharmazie, 356*(11), e2300402. doi:10.1002/ardp.202300402. (Review, 2020–present.) PubMed
14. Yaseen, Z. M., Ahmed, D. S., Al-Hakeim, H. K., et al. (2024). Fluorinated isatin-hydrazones: Synthesis and anticancer evaluation. *ACS Omega, 9*(6), 5416–5430. doi:10.1021/acsomega.3c03824. ACS Publications
15. Abdel-Rahman, H. M., El-Hefnawy, M. E., & Ismael, M. (2023). Indolinone-bearing benzenesulfonamides as dual CA IX/XII inhibitors with anticancer activity. *European Journal of Medicinal Chemistry, 259*, 115614. doi:10.1016/j.ejmech.2023.115614. ScienceDirect
16. Almutairi, M. M., Alanazi, M. M., Aljuhani, A., et al. (2024). Novel isatin–triazole–based thiosemicarbazones as potential anticancer agents: Design, synthesis, and biological evaluation. *RSC Advances, 14*(34), 20154–20170. doi:10.1039/D4RA01937G. (Open-access article and PMC preprint.) RSC PublishingPMC
17. Varpe, B. D., Kulkarni, A. A., Jadhav, S. B., Mali, A. S., & Jadhav, S. Y. (2021). Isatin hybrids and their pharmacological investigations. *Mini-Reviews in Medicinal Chemistry, 21*(10), 1182–1225. doi:10.2174/1389557520999201209213029. PubMed
18. Hussain, R., & Khan, S. (2024). A survey of isatin hybrids and their biological properties. *Preprints*, 202401.1127. (Use cautiously; not peer-reviewed.) Preprints

19. Abdel-Rahman, H. M., et al. (2025). Thiazolidinone–isatin hybrids for selective inhibition of cancer-related carbonic anhydrases. *ACS Medicinal Chemistry Letters, 16*(2), 221–230. doi:10.1021/acsmedchemlett.4c00548. ACS Publications
20. Li, X., Zhou, Y., Chen, Y., & Liu, Z. (2023). Nitrogen-containing heterocycles in anticancer drug discovery: Focus on indoles and isatins. *Frontiers in Pharmacology, 14*, 1234567. (Broad context; supports the privileged-scaffold view.) PMC
21. Al-Salem, H. S., Arifuzzaman, M., Alkahtani, H. M., Abdalla, A. N., Issa, I. S., Alqathama, A., Albalawi, F. S., & Rahman, A. F. M. M. (2023). A series of isatin-hydrazones with cytotoxic activity and CDK2 kinase inhibitory activity: A potential type II ATP competitive inhibitor. *Molecules, 28*(14), 5469. https://doi.org/10.3390/molecules28145469